Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2022-05-05 Director's Dealing
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
Director's Dealing 2022
Director's Dealing
2022-05-05 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 2, 2022, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. It details the terms of the offering, the underwriting agreement, and includes press releases announcing the offering and its pricing. The content focuses on financing activities, specifically the sale of shares and capital raising. There are no financial statements or detailed financial performance data included, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy, governance, or management report. It clearly relates to capital raising and financing updates. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2022-05-04 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by Tarsus Pharmaceuticals, Inc. It details the terms of the offering, underwriting discounts, use of proceeds, risk factors, and other offering-specific information. It is not a financial report, earnings release, or management discussion. It is a capital markets document related to fundraising and issuance of new shares. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters) and contains detailed offering information, not just an announcement or notice, supporting a high confidence classification.
2022-05-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 2, 2022, by Tarsus Pharmaceuticals, Inc. It is titled 'Current Report' and includes an 'Item 8.01 Other Events' section describing a risk factor update related to the company's clinical drug development process. The text discusses clinical trial risks, regulatory approval challenges, and other operational risks but does not contain financial statements or comprehensive financial data. The document is a regulatory filing to inform investors and the public about material events or updates outside of regular periodic reports. It is not an annual report, earnings release, or detailed financial report. The Form 8-K is a general regulatory filing used to disclose significant events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content support this classification with high confidence.
2022-05-03 English
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433 under the Securities Act of 1933. It supplements a Preliminary Prospectus Supplement and discusses risks related to clinical drug development and commercialization of product candidates. The text focuses on risk factors and regulatory considerations in connection with a contemplated public offering of shares. It is not a full financial report, earnings release, or management discussion, but rather a disclosure document related to a capital raising activity. The presence of terms like 'public offering of shares' and 'Registration Statement' indicates this is related to financing. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2022-05-03 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 2, 2022. It announces the issuance of a press release and a corporate presentation regarding positive Phase 3 trial results. The document explicitly states that the corporate presentation is filed as Exhibit 99.1 and is posted on the company's website. The text is about furnishing information and does not contain detailed financial statements or substantive financial data. The document length is 3816 characters, which is relatively short and consistent with an announcement rather than a full report. The key content is a corporate presentation related to clinical trial results, which aligns with an Investor Presentation. Therefore, the appropriate classification is Investor Presentation (IP).
2022-05-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.